Paul Hamberg

DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis

Linda M. Henricks, Carin A.T.C. Lunenburg, Femke M. de Man et al. · The Lancet Oncology · 2018 · 419 citations · Full text

Medicine, Oncology, Pharmacology +16

Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

Thomas Powles, Piotr Tomczak, Se Hoon Park et al. · The Lancet Oncology · 2022 · 278 citations · Full text

Medicine, Oncology, Pharmacotherapy +16

Efficacy of Cabazitaxel in Castration-resistant Prostate Cancer Is Independent of the Presence of AR-V7 in Circulating Tumor Cells

Wendy Onstenk, Anieta M. Sieuwerts, Jaco Kraan et al. · European Urology · 2015 · 240 citations

Medicine, Oncology, Pharmacology +13

The genomic landscape of metastatic castration-resistant prostate cancers reveals multiple distinct genotypes with potential clinical impact

Lisanne F. van Dessel, Job van Riet, Minke Smits et al. · Nature Communications · 2019 · 209 citations · Full text

Medicine, Genetics, Oncology +17

Clinical activity and tolerability of enzalutamide (MDV3100) in patients with metastatic, castration‐resistant prostate cancer who progress after docetaxel and abiraterone treatment

Sushil K. Badrising, Vincent van der Noort, Inge M. van Oort et al. · Cancer · 2013 · 135 citations

Medicine, Oncology, Pharmacology +16